Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 6/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25276580 | 0.84 | RYR2 (0.53) | RYR2ESR1ESR2ROCK1ALDH1A1 | |
| SCHEMBL30666345 | 0.84 | RYR2 (0.53) | RYR2ESR1ESR2ROCK1ALDH1A1 | |
| SCHEMBL15989340 | 0.84 | ESR1 (0.53) | RYR2ESR1ESR2ROCK1NAMPT | |
| SCHEMBL30685013 | 0.82 | ESR1 (0.52) | RYR2ESR1ESR2ROCK1NAMPT | |
| SCHEMBL31463281 | 0.82 | RYR2 (0.51) | RYR2ESR1ESR2ROCK1NAMPT | |
| SCHEMBL15880544 | 0.82 | ESR1 (0.57) | RYR2ESR1ESR2ROCK1NAMPT | |
| SCHEMBL30677763 | 0.82 | ESR1 (0.57) | RYR2ESR1ESR2ROCK1NAMPT | |
| SCHEMBL31463297 | 0.81 | NAMPT (0.57) | RYR2ESR1ESR2NAMPT | |
| SCHEMBL31463189 | 0.80 | ESR1 (0.47) | RYR2ESR1ESR2ROCK1NAMPT | |
| SCHEMBL27205831 | 0.80 | ESR1 (0.47) | RYR2ESR1ESR2ROCK1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | STING1, IRF3, CGAS | RYR2 2941/4885ESR1 3431/4885ESR2 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.